PROF 20 |
| Most drug companies are heavily invested in the traditional pharmaceutical R&D model, sometimes called the blockbuster model. Even though the return on that investment has been eroding, as judged by the declining number of NMEs approved, switching to another model is daunting. Where to start? What roadmap to follow? Should the replacement be gradual or abrupt? This presentation explores concrete steps that a traditional research organization can take to transition towards an open-innovation model. The emphasis is upon changes that require little or no capital investment, and therefore offer the prospect of early returns. It also examines the pitfalls that can derail such initiative, particularly the adjustments in process and culture that must accompany it. |
|
Opportunities in Open Innovation
2:00 PM-4:50 PM, Monday, August 20, 2007 Sheraton Boston -- Back Bay Blrm A, Oral
Division of Professional Relations |